Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

ABSTRACT:

Background

Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear.

Objective

To determine whether gDDRm status impacts benefit from established therapies in mPC.

Design, setting, and participants

This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status. All 372 patients from Royal Marsden (UK), Weill-Cornell (NY), and University of Washington (WA) were previously included in a prevalence study (Pritchard, NEJM 2016); the remaining 18 were gBRCA1/2m carriers, from the kConFab consortium, Australia.

Outcome measurements and statistical analysis

Response rate

SUBMITTER: Mateo J 

PROVIDER: S-EPMC6745088 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature